ArticleFrontiers in neurology
Safety and efficacy of intravenous tPA after successful thrombectomy for large vessel occlusion: a retrospective study.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study aimed to evaluate the efficacy and safety of adjunctive intravenous (IV) tissue plasminogen activator (tPA) administration following successful mechanical thrombectomy in patients with acute ischemic stroke caused by large vessel occlusion (LVO). Methods: This single-center retrospective study included patients with anterior circulation LVO who achieved successful recanalization (Thrombolysis in Cerebral Infarction score ≥2b) after endovascular thrombectomy (EVT) between January 2021 and December 2024. Beginning in December 2022, 25% of the standard IV tPA dose (0.6 mg/kg) was administered immediately after successful recanalization (post-IV tPA group), in addition to the standard pre-EVT 75% dose. Parenchymal blood volume (PBV) ratios were assessed using flat-panel detector computed tomography before and after EVT. The primary outcome was the modified Rankin Scale (mRS) score at 90 days. Safety outcomes were symptomatic intracranial hemorrhage (sICH), any intracranial hemorrhage (ICH), and 90-day mortality. Results: Fifty-five patients met inclusion criteria (post-IV tPA, Conclusion: Adjunctive IV tPA administration following successful EVT may improve microvascular reperfusion and functional outcomes without increasing hemorrhagic complications, although careful patient selection is warranted. Due to study limitations, results are hypothesis-generating and require further validation in future prospective randomized trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.